337 related articles for article (PubMed ID: 36773776)
1. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
Chen M; Lu H; Copley SJ; Han Y; Logan A; Viola P; Cortellini A; Pinato DJ; Power D; Aboagye EO
J Thorac Oncol; 2023 Jun; 18(6):718-730. PubMed ID: 36773776
[TBL] [Abstract][Full Text] [Related]
2. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
3. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
[TBL] [Abstract][Full Text] [Related]
7. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
8. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
9. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
10. [Construction of A Nomogram Prediction Model for PD-L1 Expression
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
Hao L; Wang L; Zhang M; Yan J; Zhang F
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
[TBL] [Abstract][Full Text] [Related]
11. [CT-Based Weighted Radiomic Score Predicts Tumor Response to Immunotherapy in Non-Small Cell Lung Cancer].
Zhu ZC; Chen MJ; Song L; Wang JH; Hu G; Han W; Tan WX; Zhou Z; Sui X; Song W; Jin ZY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Oct; 45(5):794-802. PubMed ID: 37674467
[TBL] [Abstract][Full Text] [Related]
12. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
13. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
14. What does radiomics do in PD-L1 blockade therapy of NSCLC patients?
Cui R; Yang Z; Liu L
Thorac Cancer; 2022 Oct; 13(19):2669-2680. PubMed ID: 36039482
[TBL] [Abstract][Full Text] [Related]
15. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
[No Abstract] [Full Text] [Related]
16. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Nogova L; Araceli T; Schmidt NO; Ruge MI; Goldbrunner R; Proescholdt M; Grau S; Lohmann P
J Neurooncol; 2023 Jul; 163(3):597-605. PubMed ID: 37382806
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-ligand 1 expression in non-small cell lung carcinoma - mechanism of regulation, association with other markers, and therapeutic implication.
Tancoš V; Blichárová A; Plank L
Klin Onkol; 2022; 35(5):372-376. PubMed ID: 36443097
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
